Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Novo Nordisk drops 7% after investor event

Novo Nordisk's Copenhagen-listed shares fell around 7% Monday after the Danish drugmaker unveiled new growth ambitions at its Capital Markets Day, including plans to launch more than five drugs with

Novo Nordisk shares fall 6% as company sets 2030 growth targets By Investing.com

Novo Nordisk shares fall 6% as company sets 2030 growth targets

Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals

Novo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.

Novo Touts Future Blockbuster Launches, Disappointing Investors

Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.

Novo shares slide as drugmaker lays out post-Wegovy growth strategy

The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.

Novo Nordisk shares fall after 2030 strategic targets

Novo Nordisk shares declined after the company outlined 2030 goals, including pipeline sales targets and obesity market expansion plans.